Science

$Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML$

Naveen Pemmaraju/mdanderson.org

Apr 20, 2025, 12:33

Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Our group’s new article led by Dr Hannah Goulart and Dr Tapan Kadia Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia (AML).”

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Authors: Hannah Goulart, et al.

$Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML$

Acute Myeloid Leukemia AML BPDCN Program cancer Cladribine CLIA cytarabine fight against cancer Global fight against cancer Hannah Goulart idarubicin MD Anderson Cancer Center Naveen Pemmaraju OncoDaily Oncology Tapan Kadia University of Texas

Marking One Year of Progress in IDH-Mutant Glioma Treatment - Servier Pharmaceuticals

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

A Pivotal Day for Geron

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology